PureTech Appoints UBS as Corporate Broker

PRTC 01.06.2025

Full Press ReleaseSEC FilingsOur PRTC Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - PureTech to Present at the 43rd Annual J.P. Morgan Healthcare Conference
  • 01.09.2025 - PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
  • 01.08.2025 - PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 12.16.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
  • 12.16.2024 - EX-99.1 EX-99.1
PDF Version
RNS Number : 1539S
PureTech Health PLC
06 January 2025

6 January 2025

PureTech Health plc

PureTech Appoints UBS as Corporate Broker

PureTech Health plc(Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), is pleased to announce that it has appointedUBSas itsUKCorporate Broker.

AboutPureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by theU.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

For more information, visitwww.puretechhealth.comor connect with us on X (formerly Twitter) @puretechh.

Contact:

PureTech

Public Relations

publicrelations@puretechhealth.com

InvestorRelations

IR@puretechhealth.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of theLondon Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contactrns@lseg.comor visitwww.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and theLondon Stock Exchangeuse the personal data you provide us, please see ourPrivacy Policy.

END

NRASSDFAIEISELF

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com